Results 191 to 200 of about 22,691 (214)

Long-acting muscarinic antagonists

Expert Review of Clinical Pharmacology, 2015
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major class of inhaled bronchodilators.
openaire   +2 more sources

Emerging muscarinic receptor antagonists for the treatment of asthma

Expert Opinion on Emerging Drugs, 2020
The increased acetylcholine signaling in asthma pathophysiology offers the rationale for the use of LAMAs in the treatment of asthmatic patients. Tiotropium is still the only LAMA approved for use in asthma but there is a real interest in developing novel LAMAs for the treatment of asthma, or at least to extend this indication to other LAMAs already on
Maria Gabriella, Matera, Carmela, Belardo, Michele, Rinaldi, Barbara, Rinaldi, Mario, Cazzola   +4 more
openaire   +4 more sources

Muscarinic Antagonists for Myopia Control

1998
Previous nonsurgical treatment of myopia using optical and pharmaceutical agents has not allowed an unequivocal consensus. Such studies must be based on the natural history of myopia progression, accurate biometric measurements, and randomized clinical trials.
Hong-Ming Cheng, Hong-Ming Cheng, Sek-Jin Chew, Sek-Tien Hoh, Jenny Tan   +4 more
openaire   +2 more sources

Muscarinic autoreceptors are differentially affected by selective muscarinic antagonists in rat hippocampus

Neurochemistry International, 1989
The effects of atropine, pirenzepine and AF-DX 116 on the high K(+)-evoked release of endogenous ACh from rat hippocampal slices were compared. As expected, atropine in concentrations of 10(?5) and 10(?6)M increased the release of acetylcholine, to 128 and 157% of the control value, respectively. While AF-DX 116 was also able to increase the release to
Dénes Budai, Peter Kasa, Karoly Gulya
openaire   +3 more sources

Improved Muscarinic Antagonists as Anticholinesterase Antidotes [PDF]

, 1990
Abstract : Muscarinic antagonists play an important role in anticholinesterase agent therapy by reducing the response of muscarinic receptors to acetylcholine, acting synergistically with cholinesterase reactivators. Therapy with antagonists such as atropine is difficult to manage because of the toxicity of these compounds, atropine antagonizes the ...
openaire   +1 more source

Muscarinic agonists and antagonists in the treatment of Alzheimer's disease

Il Farmaco, 2001
Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and personality changes. The development of drugs for the treatment of the cognitive deficits of AD has focused on agents which counteract loss in cholinergic activity. Although symptoms of AD have been successfully treated with acetylcholinesterase inhibitors
Vicki L. Coffin, Stuart W. McCombie, William Billard, Robert W. Watkins, Joseph A. Kozlowski, William J. Greenlee, C Liu, Jean E. Lachowicz, Lisa A. Taylor, Vilma Ruperto, Catherine D. Strader, Henry Guzik, Vice Susan F, Herbert Binch, Shengjian Li, Ruth A. Duffy, Derek B. Lowe, H Zhao, Kathleen Cox, Theodros Asberom, R Crosby, Gouwei Zhou, Jennifer Ford, John W. Clader   +23 more
openaire   +3 more sources

Selective muscarinic receptor antagonists for airway diseases

Current Opinion in Pharmacology, 2001
Airway tone and airway hyperreactivity are mediated by the parasympathetic nerves that release acetylcholine onto muscarinic receptors (M1-M5). Stimulation of M1 and M3 muscarinic receptors causes bronchoconstriction. The M1 muscarinic receptor is excitatory, and facilitates neuronal transmission at the parasympathetic ganglion.
David B. Jacoby, Ann M. Lee, Allison D. Fryer   +2 more
openaire   +3 more sources

Role of muscarinic receptor antagonists in urgency and nocturia

BJU International, 2005
The overactive bladder (OAB) syndrome is defined as urgency, with or without urgency incontinence, usually accompanied by frequency and nocturia. Muscarinic receptor antagonists are the most established form of treatment for OAB, but until recently their effectiveness was only confirmed for symptoms of incontinence and frequency.
Martin C. Michel, Jean J.M.C.H. de la Rosette   +1 more
openaire   +3 more sources

MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER

BJU International, 2000
ABSTRACTA wealth of clinical evidence supports the view that muscarinic receptor antagonists are effective in the treatment of overactive bladder. However, treatment‐limiting adverse effects such as dry mouth, constipation, and blurred vision have restricted the usefulness of previously available agents, such as oxybutynin.
openaire   +4 more sources

Muscarinic Agonists and Antagonists: Effects on the Urinary Bladder

2011
Voiding of the bladder is the result of a parasympathetic muscarinic receptor activation of the detrusor smooth muscle. However, the maintenance of continence and a normal bladder micturition cycle involves a complex interaction of cholinergic, adrenergic, nitrergic and peptidergic systems that is currently little understood.
Sellers, Donna J., Chess-Williams, Russ
openaire   +3 more sources